Using the continual reassessment method: Lessons Learned from an EORTC phase I dose finding study

European Journal of Cancer

Volumn 42, Issue 10, 2006, Pages 1362-1368

  Paoletti, Xavier ^a   Baron, Benoît ^b   Schöffski, Patrick ^c   Fumoleau, Pierre ^d   Lacombe, Denis ^b   Marreaud, Sandrine ^b   Sylvester, Richard ^b  

^a BICHAT HOSPITAL   (France)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Composite endpoint; Dose finding; Dose toxicity model; Maximum tolerated dose

Indexed keywords

ANTINEOPLASTIC AGENT; RVISCUMIN; UNCLASSIFIED DRUG;

ARTICLE; ASTHENIA; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG SAFETY; HUMAN; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; SAFETY; VISCUM ALBUM;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; HUMANS; MAXIMUM TOLERATED DOSE; PHYTOTHERAPY; PLANT PREPARATIONS; PLANT PROTEINS; RISK FACTORS; TOXINS, BIOLOGICAL;

EID: 33745236089     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.01.051     Document Type: Article

References (24)

1. Roberts T.G., Goulart B.H., Squitieri L., et al. Trends in the Risks and Benefits to Patients with Cancer Participating in Phase 1 Clinical Trials. JAMA 292 17 (2004) 2130-2140
2. Eisenhauer E.A., O'Dwyer P.J., Christian M., et al. Phase I clinical trials design in cancer drug development. J Clin Oncol 18 (2000) 684-692
3. O'Quigley J., Pepe M., and Fisher L. Continual Reassessment Method: a practical method for phase I trials. Biometrics 46 (1990) 33-48
4. Geoerger B., Vassal G., Doz F., et al. Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. Br J Cancer. 93 5 (2005) 529-537
5. Khuri F.R., Glisson B.S., Kim E.S., et al. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumours. Clin Cancer Res. 10 9 (2004) 2968-2976
6. Eder Jr. J.P., Garcia-Carbonero R., Clark J.W., et al. A phase I trial of daily oral 4′- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs 22 2 (2004) 139-150
7. Goodman S.N., Zahurak M.L., and Piantadosi S. Some Practical Improvements in the Continual Reassessment Method for Phase I Studies. Stat Med 14 11 (1995) 1149-1161
8. Dent S.F., and Eisenhauer E.A. Phase I trial design: are new methodologies being put into practice?. Ann Oncol 7 (1996) 561-566
9. Schöffski P., Riggert S., Fumoleau P., et al. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumours: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol 15 12 (2004) 1816-1824
10. O'Quigley J., and Shen L.Z. Continual Reassessment Method: A likelihood approach. Biometrics 52 (1996) 395-405
11. Thall P.F., Lee J.J., Tseng C.H., et al. Accrual strategies for phase I trials with delayed patient outcome. Stat Med 18 10 (1999) 1155-1169
12. O'Quigley J., and Reiner E. A stopping rule for the Continual Reassessment Method. Biometrika 85 3 (1998) 741-748
13. Paoletti X., O'Quigley J., and Maccario J. Design Efficiency in Dose Finding Studies. Computational Statistics and Data Analysis 45 2 (2004) 197-214
14. Ahn C. An evaluation of phase I cancer clinical trial designs. Stat Med 17 (1998) 1537-1549
15. Storer B. Choosing a Phase I Design in Handbook of Statistics in Clinical Oncology. In: John Crowley editor, Handbook of Statistics in Clinical Oncology. NY, Crowley, 2001, 73-91.
16. Storer B.E. Design and analysis of phase I clinical trials. Biometrics 45 3 (1989) 925-937
17. Durham S.D., Flournoy N., and Rosenberger W.F. A random Walk rule for phase I clinical trials. Biometrics 53 (1997) 745-760
18. Simon R., Freidlin B., Rubinstein L., Arbuck S.G., Collins J., and Christian M.C. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89 15 (1997) 1138-1147
19. Piantadosi S., and Liu G. Improved designs for dose escalation studies using Pharmacokinetics Measurements. Stat Med 15 (1995) 1605-1618
20. Zohar S., and Chevret S. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Stat Med. 20 19 (2001) 2827-2843
21. Bekele B.N., and Thall P.F. Dose Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial. JASA 89 465 (2004) 26-35
22. Whitehead J. A unified theory for sequential clinical trials. Stat Med. 18 17-18 (1999) 2271-2286
23. Schoffski P., Breidenbach I., Krauter J., et al. Weekly 24-h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. Eur J Cancer 41 10 (2005) 1431-1438
24. Christian M.C., and Korn E.L. The limited precision of phase I trials. J Natl Cancer Inst 16 86 (1994) 1662-1663